Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/054818external-prioritypatent/WO2013135602A2/en
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Publication of MA35927B1publicationCriticalpatent/MA35927B1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La présente invention concerne des méthodes de traitement d'un patient chez qui on a diagnostiqué un cancer de l'ovaire résistant au platine comprenant l'administration au dit patient d'une quantité efficace d'un anticorps anti-vegf et d'un agent chimiothérapique.The present invention relates to methods of treating a patient diagnosed with platinum-resistant ovarian cancer comprising administering to said patient an effective amount of an anti-vegf antibody and an agent. chemotherapy.
MA37330A2012-03-132014-09-05
Combination therapy for the treatment of ovarian cancer
MA35927B1
(en)
Protein specific membrane antigen (psma) labeled inhibitors, their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer